Immune Pharmaceuticals, Inc. (OTCMKTS:IMNPQ) Short Interest Update

Immune Pharmaceuticals, Inc. (OTCMKTS:IMNPQ) was the recipient of a large growth in short interest during the month of May. As of May 28th, there was short interest totalling 51,000 shares, a growth of 50,900.0% from the May 13th total of 100 shares. Based on an average trading volume of 1,052,000 shares, the short-interest ratio is presently 0.0 days.

Shares of IMNPQ stock traded up $0.00 on Friday, reaching $0.00. 120,997 shares of the company’s stock were exchanged, compared to its average volume of 3,260,849. Immune Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.18. The business has a fifty day moving average of $0.05.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis.

Recommended Story: Why do company’s buyback their stock?

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.